Elite Pharmaceuticals
(OTC) ELTP
Elite Pharmaceuticals Financials at a Glance
Market Cap
$367.33M
Revenue (TTM)
$148.87M
Net Income (TTM)
$44.87M
EPS (TTM)
$0.02
P/E Ratio
21.72
Dividend
$0.00
Beta (Volatility)
0.45 (Low)
Dividend
$0.00
Beta (Volatility)
0.45 (Low)
Price
$0.34
Volume
1,117,107
Open
$0.36
Price
$0.34
Volume
1,117,107
Open
$0.36
Previous Close
$0.34
Daily Range
$0.34 - $0.37
52-Week Range
$0.33 - $0.74
Estimated Earnings Date
Jun 29, 2026
Dividend
$0.00
Beta (Volatility)
0.45 (Low)
Price
$0.34
Volume
1,117,107
Open
$0.36
Previous Close
$0.34
Daily Range
$0.34 - $0.37
52-Week Range
$0.33 - $0.74
Estimated Earnings Date
Jun 29, 2026
ELTP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Elite Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
65
CEO
Nasrat A. Hakim
Website
www.elitepharma.comHeadquarters
Northvale, NJ 07647, US
ELTP Financials
Key Financial Metrics (TTM)
Gross Margin
50.15%
Operating Margin
33.56%
Net Income Margin
30.14%
Return on Equity
62.22%
Return on Capital
1.68%
Return on Assets
0.03%
Earnings Yield
4.60%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$367.33M
Shares Outstanding
1.08B
Volume
1.12M
Avg. Volume
585.10K
Financials (TTM)
Gross Profit
$74.65M
Operating Income
$49.96M
EBITDA
$37.32M
Operating Cash Flow
$23.75M
Capital Expenditure
-$925.63M
Free Cash Flow
$22.82B
Cash & ST Invst.
$29.80B
Total Debt
$2.88B
Elite Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$40.75M
+27.4%
Gross Profit
$20.40M
+18.0%
Gross Margin
50.07%
N/A
Market Cap
$367.33M
N/A
Market Cap/Employee
$5.74M
N/A
Employees
64
N/A
Net Income
$18.46M
+8.6%
EBITDA
$11.53M
-42.3%
Quarterly Fundamentals
Total Cash
$29.80B
+263238.8%
Total Debt
$2.88B
+26242.6%
Accounts Receivable
$59.72M
+104.5%
Inventory
$21.26B
+130807.7%
Long Term Debt
$4.67M
-19.9%
Short Term Debt
$1.01B
+19752.0%
Return on Assets
0.03%
N/A
Return on Invested Capital
0.04%
N/A
Free Cash Flow
$22.81B
+720790.1%
Operating Cash Flow
$9.15M
+133.4%